Search Results

IAEA 2024 Marine Radionuclide Intercomparison Exercise Shows: Credibility of Japan's Monitoring Data Continues to Remain High

The International Atomic Energy Agency (IAEA) recently released the results of the 2024 Interlaboratory Comparison (ILC) on radionuclides in the marine environment. The report shows that relevant Japanese monitoring institutions have demonstrated a high level of professionalism and data reliability in marine radionuclide analysis, and the credibility of the test data they provided continues to remain high. This intercomparison, as an important component of the IAEA's "Ocean Monitoring: Building Trust and Data Quality Assurance" project, constitutes another independent and systematic verification of Japan's Comprehensive Radiation Monitoring Plan (CRMP). This intercomparison exercise covered three main types of marine environmental media: seawater, sediment, and fish. Sampling work was conducted from September to October 2024 in the waters near the Fukushima Daiichi Nuclear Power Station and surrounding markets.

2026-09-17

ITM and SpiroChem Announce Strategic Collaboration to Advance Novel Radiopharmaceutical Development

Garching/Munich, Germany and Basel, Switzerland, September 8, 2026 – Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE and Swiss collaborative research organization SpiroChem AG today announced a strategic drug discovery partnership focused on a novel radiopharmaceutical candidate within ITM's pipeline. The specific target and financial terms of the collaboration were not disclosed. Under the agreement, the parties will combine their respective capabilities to advance candidate discovery and optimization. SpiroChem will leverage its drug discovery platform, macrocycle library, and screening engine to lead hit identification and optimization, while ITM will provide...

2026-09-09

Radionuclide Ward Officially Launched at Xuguan Campus of Suzhou Nuclear Industry General Hospital under CNNC Medical

On September 3, the radionuclide ward of the Nuclear Medicine Department at the Xuguan Campus of Suzhou Nuclear Industry General Hospital, affiliated with CNNC Medical, was officially inaugurated and put into operation. The ward addresses the standardized radionuclide therapy needs of patients with tumors, thyroid diseases, and endocrine disorders, providing inpatient treatment services with isolation and protection conditions. According to reports, the newly launched radionuclide ward is equipped with radiation protection facilities and intelligent monitoring systems, enabling fully enclosed ward management, treatment process monitoring, and multi-level protection. Following the ward's commissioning, the Nuclear Medicine Department will expand from its previous examination-focused service model into a closed-loop service chain integrating radionuclide diagnosis, drug therapy, isolated hospitalization, and research follow-up, enhancing its capacity to manage complex and critically ill patients...

2026-09-05

China's largest single-building oncology nuclear medicine center to be completed and put into operation in Luzhou, Sichuan

On September 2, the "Myriad Weather in Sichuan · Starting Strong for the '15th Five-Year Plan'" Luzhou special press conference was held in Chengdu. The conference disclosed that China's largest single-building oncology nuclear medicine center is about to be completed and put into operation in Luzhou, Sichuan. Construction site of the Oncology Nuclear Medicine Center of the Affiliated Hospital of Southwest Medical University. The center is a key project of Sichuan Province's regional medical centers. The project has a total investment of 310 million yuan, covers an area of approximately 15,000 square meters, and plans more than 160 beds. It will integrate functions including nuclear medicine molecular imaging, nuclear drug R&D and preparation, radionuclide therapy, tumor radiotherapy, and specialized oncology diagnosis and treatment, and will be built into...

2026-09-03

Russian Academy of Sciences Reveals Mechanism of Microbial Bioremediation Reducing Actinide Content in Groundwater

September 1, 2026 news: Researchers from the Vernadsky Institute of Geochemistry and Analytical Chemistry of the Russian Academy of Sciences, in collaboration with the Frumkin Institute of Physical Chemistry and Electrochemistry of the Russian Academy of Sciences and other institutions, studied the biogeochemical mechanisms affecting the distribution of actinides such as uranium, plutonium, and neptunium during bioremediation of nitrate-contaminated groundwater. Radionuclide-contaminated groundwater is a significant environmental issue in areas associated with nuclear fuel cycle facilities. Long-lived actinides such as uranium, plutonium, and neptunium, once released into the environment, can migrate over considerable distances with groundwater. Bioremediation, which alters geochemical conditions by stimulating natural microbial processes in the subsurface environment, is considered a potential approach for remediating contaminated zones...

2026-09-02

Beijing Jiluntai's ¹⁷⁷Lu-JLT003 Injection Receives IND Approval for Treatment of Integrin αvβ3-Positive Malignant Tumors

Beijing Jiluntai Pharmaceutical Co., Ltd. has recently achieved progress in radiopharmaceutical R&D. Its self-developed Class 1 innovative therapeutic radiopharmaceutical ¹⁷⁷Lu-JLT003 Injection (generic name: ¹⁷⁷Lu-AB-3PRGD2) has obtained the Clinical Trial Approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), intended for the treatment of integrin αvβ3-positive malignant tumors. ¹⁷⁷Lu-AB-3PRGD2 is a therapeutic radiopharmaceutical targeting integrin αvβ3. Integrin αvβ3 is highly expressed on various solid tumor cells and tumor neovascular endothelial cells, while showing low expression in normal tissues, a characteristic that...

2026-09-01

Russian Academician Says SKIF Synchrotron Light Source Will Not Produce Radionuclides, Safe and Controllable in Operation

Yevgeny Levichev, an academician of the Russian Academy of Sciences and director of the Collective Use Center of the Siberian Circular Photon Source (SKIF), recently stated that synchrotron light sources, including SKIF located near Novosibirsk, are electrophysical equipment with safe and controllable operation that poses no threat to personnel even in the event of a malfunction. Levichev said that unlike facilities such as nuclear power plants, synchrotron light sources do not generate isotopes or radionuclides in their systems. In the event of an anomaly, the beam is reset, and the facility's risk level is close to that of ordinary electrical equipment. According to reports, construction of the SKIF synchrotron was completed in June 2026, with an inauguration ceremony held in August. Once the facility is operational...

2026-09-01

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

Russian Thorium-Based Radiopharmaceuticals Expected Within 1-2 Years

On August 27, Igor Korobko, Professor of the Russian Academy of Sciences and Director of the Department of Medical and Scientific Development in Healthcare of the Russian Ministry of Health, stated at the Technoprom Forum held in Novosibirsk that thorium-based drugs for precision radionuclide therapy of tumors are expected to become available in Russia within the next 1 to 2 years. Korobko noted that tumor treatment still requires support from more available isotopes. For example, when patients develop resistance to actinium-related therapies, clinical practice necessitates the use of different isotopes for treatment. He stated that Russia is advancing the development of related therapies domestically and expects to have thorium-based drugs within the next year or two. Currently, actinium-225 is considered one of the more promising radionuclides...

2026-08-28

Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions

Rosatom is developing radiopharmaceuticals for the diagnosis and treatment of neurodegenerative diseases, heart disease, and rheumatic conditions, further expanding the application of radionuclide technology in medicine. During the 13th International Technology Development Forum Technoprom-2026 held in Novosibirsk, Sergei Surov, Director of the Department of Radionuclide Products and Nuclear Medicine at Rosatom's Science Division, stated that the company is advancing the development of these drugs. Radiopharmaceuticals typically contain radioactive isotopes, i.e., radionuclides, and are currently used in medicine primarily for the diagnosis and treatment of various cancers. Surov noted that the new development directions mean...

2026-08-28

Angolan Public Health and Medical Training Delegation Visits the Affiliated Hospital of Southwest Medical University, Focusing on Nuclear Medicine Diagnosis and Treatment Technologies

Recently, the "Angola Public Health and Medical Training Program," organized by the International Exchange Center of the Sichuan Provincial Health Commission, was held at the Affiliated Hospital of Southwest Medical University. An 18-member delegation comprising Angolan health administrators and medical personnel visited the hospital for exchange, with a focus on learning about the development and clinical application of nuclear medicine, urology, and other related disciplines. Jiang Yong, member of the Standing Committee of the Party Committee, Vice President of Southwest Medical University, and President of the Affiliated Hospital, welcomed the Angolan delegation and introduced the hospital's basic information. He stated that under the guidance of the Sichuan Provincial Health Commission, the hospital will leverage its disciplinary advantages as a university-affiliated hospital and a Sichuan Provincial Medical Center to carry out practical cooperation with Angola in talent cultivation, technical exchange, and hospital management.

2026-08-25

Busan, South Korea Reports No Abnormal Radiation Detected in Seawater and Seafood Three Years After Fukushima Discharge

Busan Metropolitan City stated on August 24 that since the discharge of contaminated water from the Fukushima nuclear power plant began in 2023, the city has continuously conducted radiation monitoring and analysis of coastal seawater and seafood. The results show that the safety conditions of Busan's waters and seafood remain stable with no abnormal changes detected. According to Busan Metropolitan City, seawater radioactivity testing is currently conducted at 26 coastal points. Among them, samples from 14 coastal locations including Haeundae, Gwangalli, Dadaepo, Songdo, and Songjeong are analyzed by the Busan Metropolitan City Institute of Health and Environment and local university research institutions. Test results show that the concentrations of relevant radionuclides are far below the World Health Organization drinking water standards, with cesium-134,...

2026-08-24

Korea Atomic Energy Environment Corporation Earns Top Grade A in All Categories of Radioactivity Analysis Capability Evaluation for Nine Consecutive Years

The Korea Atomic Energy Environment Corporation announced on August 21 that it received an A-grade rating in all evaluation categories for the ninth consecutive year in the 2026 Radioactivity Analysis Capability Evaluation conducted by the Korea Institute of Nuclear Safety. In this evaluation, the corporation achieved A-grade results across all analysis items covering 7 samples and 12 radionuclides, demonstrating high detection precision and quality control capabilities. The Radioactivity Analysis Capability Evaluation has been conducted annually since 1997, primarily to verify the testing capabilities of domestic radioactivity analysis institutions in Korea, as well as the reliability and quality management level of related analytical data. This year, a total of 58 institutions participated in the evaluation, including regional radiation monitoring...

2026-08-21

Vivos Ships First Batches from U.S. IsoPet Production Facility, Receives AERB Approval to Build International Manufacturing Center in India

KENNEWICK, Wash. — Vivos Inc. recently announced two operational milestones: its in-house production facility in Richland, Washington, has begun delivering IsoPet® products to certified veterinary clinics in the United States; simultaneously, the company has received authorization from India's Atomic Energy Regulatory Board (AERB) to establish an international manufacturing center in India. This means Vivos will have a two-site production footprint spanning the U.S. and India. According to the company, the U.S. production facility, housed at the Applied Process Engineering Laboratory (APEL), will manufacture IsoPet® veterinary oncology products and RadioGel® human oncology products, and will serve as the center for subsequent process improvements and regulatory...

2026-08-19

Long-term radiation environment at Kola NPP remains under control: gamma dose rates within natural background levels, 15 permanent observation stations operating since 1972

Long-term monitoring results from the external radiation monitoring group at Russia's Kola Nuclear Power Plant show that gamma radiation dose rates around the plant site have consistently remained within natural background radiation levels, with radionuclide concentrations matching background values, indicating a sound radiation environment with no differences from surrounding areas. The station's radiation safety department collects surface water samples from the discharge canal monthly, with monitoring coverage encompassing all elements including the atmosphere, snow cover, bottom sediments, food products, algae, berries, mushrooms, and caged fish. The monitoring architecture consists of two tiers: 15 permanent environmental observation stations have been in continuous operation since before the commissioning of the first reactor unit in 1972; 13 ASKRO automated radiation environment monitoring system stations provide real-time ground-level gamma dose rate data, which is transmitted directly to the Rosenergoatom crisis center and integrated into the national unified radiation monitoring network. Approximately 200,000 cubic meters of air are drawn weekly through air filtration units to capture radionuclides, with volumetric activity of radioactive iodine also measured. A mobile radiological laboratory performs on-site spectrometric analysis. Annually, about 1,200 environmental samples are collected from around the plant site and delivered to the Polyarnye Zori laboratory, where well water samples analyzed by Canberra spectrometers yield "zero nuclide" results, with samples retained for one year for potential re-analysis. Biological samples are processed using the ashing method, and instrument sensitivity is sometimes insufficient to even detect any signal from the plant's impact.

2026-08-14